Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chiglitazar - Chipscreen Biosciences

Drug Profile

Chiglitazar - Chipscreen Biosciences

Alternative Names: CS-038

Latest Information Update: 23 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chipscreen Biosciences
  • Class Antidementias; Antihyperglycaemics; Carbazoles; Propionic acids; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus
  • No development reported Parkinson's disease

Most Recent Events

  • 19 Sep 2019 Preregistration for Type 2 diabetes mellitus in China (PO)
  • 07 Jun 2019 Safety and efficacy data from a phase III trial in Type 2 diabetes mellitus presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
  • 28 Sep 2018 No recent reports of development identified for preclinical development in Parkinson's-disease in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top